Given the limited set of T cell receptor (TCR) V genes that are used to create TCRs that are reactive to different ligands, such as major histocompatibility complex (MHC) class I, MHC class II, and MHC-like proteins (for example, MIC molecules and CD1 molecules), the V␦1 segment can be rearranged with D␦-J␦-C␦ or J␣-C␣ segments to form classical ␥␦TCRs or uncommon ␣TCRs using a V␦1 segment (␦/␣TCR). Here we have determined two complex structures of the ␦/␣TCRs (S19-2 and TU55) bound to different locus-disparate MHC class I molecules with HIV peptides (HLA-A*2402-Nef138-10 and HLA-B*3501-Pol448-9). The overall binding modes resemble those of classical ␣TCRs but display a strong tilt binding geometry of the V␦1 domain toward the HLA ␣1 helix, due to a conserved extensive interaction between the CDR1␦ loop and the N-terminal region of the ␣1 helix (mainly in position 62). The aromatic amino acids of the CDR1␦ loop exploit different conformations ("aromatic ladder" or "aromatic hairpin") to accommodate distinct MHC helical scaffolds. This tolerance helps to explain how a particular TCR V region can similarly dock onto multiple MHC molecules and thus may potentially explain the nature of TCR cross-reactivity. In addition, the length of the CDR3␦ loop could affect the extent of tilt binding of the V␦1 domain, and adaptively, the pairing V domains adjust their mass centers to generate differential MHC contacts, hence probably ensuring TCR specificity for a certain peptide-MHC class I (pMHC-I). Our data have provided further structural insights into the TCR recognition of classical pMHC-I molecules, unifying cross-reactivity and specificity.IMPORTANCE The specificity of ␣ T cell recognition is determined by the CDR loops of the ␣TCR, and the general mode of binding of ␣TCRs to pMHC has been established over the last decade. Due to the intrinsic genomic structure of the TCR ␣/␦ chain locus, some V␦ segments can rearrange with the C␣ segment, forming a hybrid V␦C␣VC TCR, the ␦/␣TCR. However, the basis for the molecular recognition of such TCRs of their ligands is elusive. Here an ␣TCR using the V␦1 segment, S19-2, was isolated from an HIV-infected patient in an HLA-A*24:02-restricted man-